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Abstract: The US Food and Drug Administration (FDA) recently approved lorcaserin and the 
combination of phentermine and extended release topiramate (phentermine/topiramate ER) for 
the treatment of obesity in conjunction with a lifestyle intervention, expanding the therapeu-
tic options for long-term obesity pharmacotherapy, which was previously limited to orlistat. 
Combination phentermine/topiramate ER is associated with greater weight loss compared to its 
constituent monotherapy, with a more favorable adverse effect profile. Phentermine/ topiramate 
ER also appears to have beneficial effects on cardiometabolic risk, although longer-term 
cardiovascular safety data are required. While there are no head-to-head studies among the 
currently available obesity pharmacotherapy agents, phentermine/topiramate ER appears to 
have a superior weight loss profile. This review will discuss the epidemiology, natural his-
tory, and cardiometabolic risk associated with obesity, provide an overview on current obesity 
pharmacotherapy, and summarize the recent clinical efficacy and safety data underpinning the 
FDA’s approval of both phentermine/topiramate ER and lorcaserin as pharmacotherapy for a 
long-term obesity intervention.
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Introduction
epidemiology and the natural history of obesity
Obesity is a chronic disease that has become a serious global threat to public health, 
with the worldwide prevalence of obesity exponentially increasing. Recent World 
Health Organization data reveal that 35% of adults are overweight and 11% of adults 
are obese, corresponding to an estimated 1.46 billion overweight and 500 million 
obese adults, respectively.1 This equates to almost double the incidence of obesity in 
1980, while the age-standardized mean global body mass index (BMI) increased by 
0.4–0.5 kg/m2 per decade in both men and women.1
The US now accounts for the highest global incidence of overweight and obesity, 
particularly in men, with the respective lifetime risk of approximately 50% and 25%.2 
Future projections indicate that if the current US trajectory is not curbed, by 2030, close 
to half of all men and women will be obese.3 Despite these alarming statistics, only 
one-third of obese patients receive an obesity diagnosis or weight-related  treatment 
advice from their physicians.4
Cardiometabolic sequelae of obesity
Obesity is caused by an interaction of environmental factors, genetic predisposition, and 
human behavior that confers increased risk of morbidity and mortality predominantly 
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through cardiometabolic sequelae.5 Evidence suggests that 
obesity is implicated in close to 3 million deaths worldwide 
every year.6 Overweight and obese patients are at an increased 
risk of developing cardiometabolic complications including 
hypertension, type 2 diabetes mellitus, dyslipidemia, and 
cardiovascular diseases, as well as conditions such as osteoar-
thritis, obstructive sleep apnea, hepatobiliary diseases, and 
certain malignancies.1
Weight reduction of 5%–10% from baseline is associated 
with improvements in cardiometabolic risk, with consequent 
reductions in obesity-related morbidity and mortality rates,7,8 
providing the rationale for interventions that target even 
modest weight loss.
The poor history of obesity pharmacotherapy illus-
trates the critical importance of long-term cardiovascular 
safety data in the risk–benefit analysis of newer agents. 
 Fenfluramine, dexfenfluramine, combination fenfluramine/
phentermine, and sibutramine have all been withdrawn from 
the market because of significant cardiovascular safety con-
cerns, including increased risk of nonfatal myocardial infarc-
tion and nonfatal stroke (sibutramine),9 primary pulmonary 
hypertension (combination fenfluramine/phentermine),10 and 
valvular regurgitation (fenfluramine, dexfenfluramine).11 
 Nevertheless, analysis of the major trials of failed pharma-
cotherapy, such as the Sibutramine Cardiovascular Outcomes 
(SCOUT) study,9 are invaluable in minimizing adverse 
outcomes with obesity pharmacotherapy by identifying the 
most appropriate patient population in which to use these 
agents. For example, the SCOUT study demonstrated that 
only patients with pre-existing cardiovascular disease had an 
increased risk of new cardiovascular events, and thus newer 
pharmacotherapy may be unsafe in patients with significant 
comorbidities and must be used with caution.9 Interpretation 
of the SCOUT data also suggests that the long-term continu-
ation of therapy, despite not achieving weight loss, may have 
confounded the results. Thus, pharmacotherapy should be 
ceased if patients do not achieve .5% weight loss in order 
to minimize the long-term risks of therapy.12
Review of current pharmacotherapy 
available for  obesity: efficacy,  
safety, and tolerability including  
impact on comorbidities
Prior to the US Food and Drug Administration (FDA) 
approval of lorcaserin and phentermine/topiramate extended 
release (ER), the only FDA-approved long-term obesity 
pharmacotherapy was orlistat; the latter remains the only 
long-term therapy approved in Europe. These therapies are 
approved as an adjunct to lifestyle interventions for the treat-
ment of overweight adults with comorbidities, and of obese 
patients with or without comorbidities.20
Four monotherapies have been approved for the short-
term (#3 months) management of obesity: phentermine; 
diethylpropion; benzphetamine; and phendimetrazine.13 
Only phentermine and diethylpropion are available in 
the US.
Phentermine
The noradrenergic sympathomimetic amine agent, phen-
termine, was approved by the FDA in 1959 for short-term 
(#12 weeks) obesity treatment, in addition to lifestyle 
interventions, in obese or overweight adults with obesity-
related comorbidities. It is the most commonly prescribed 
appetite suppressant in the US. While the exact mechanism 
of action is unknown, phentermine acts centrally to induce 
appetite suppression through the upregulation of dopamine, 
noradrenaline, and serotonin activity, and it has also been 
proposed to increase energy expenditure.14,15
Prior to the introduction of phentermine/topiramate ER, 
phentermine was the most effective obesity pharmacotherapy 
for both weight reduction and improvement in a number of 
comorbidities, particularly waist circumference and lipid 
profiles.16 A meta-analysis of six placebo-controlled random-
ized trials published between 1975 and 1999 of 2–24 weeks 
duration found that phentermine therapy was associated with 
a 3.6 kg (confidence interval [CI]: 0.6–6.0 kg) greater weight 
loss compared with placebo.17
Safety concerns for phentermine relate primarily to its 
cardiovascular risk factor profile, which is associated with 
phentermine’s stimulant properties, and are dose-dependent. 
Long-term clinical trials also indicate that there is increased 
tolerance and dependency associated with prolonged use.18 
The most common adverse events, typical of sympathomi-
metic amines, include dry mouth and insomnia,19 which were 
generally self-limiting and mild–moderate in clinical trials. 
More serious complications include palpitations, tachycardia, 
and hypertension. Moreover phentermine has been associ-
ated with cardiovascular complications including primary 
pulmonary hypertension, cardiovascular disease, and cardio-
vascular or cerebrovascular events, and it is contraindicated 
in individuals with these conditions, in those with psychiatric 
disorders, including anorexia or depression, or in those at 
risk of drug dependency.20
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Topiramate
Topiramate is a sulfamate-substituted monosaccharide 
approved by the FDA in 1996 for the treatment of seizure 
disorders, and for migraine prophylaxis in 2004. It is associ-
ated with significant weight loss and maintenance; however, 
it is not approved for obesity monotherapy owing to its 
adverse effects profile, which is dose related. The specific 
mechanism for topiramate associated weight loss is unclear; 
however, it does mediate appetite suppression, satiety, and 
leads to a reduction in addictive food craving by antagoniz-
ing excitatory voltage-gated sodium and calcium channels, 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
and kainite receptors, and it also modifies the taste of food 
by inhibiting carbonic anhydrase isoenzymes.21,22 Animal 
studies also implicate increased energy expenditure by 
augmenting the activity of the inhibitory neurotransmitter 
γ-aminobutyric acid.19,22,23 Furthermore, topiramate appears 
to attenuate the adverse metabolic sequelae associated 
with obesity, independent of its weight loss properties, 
by enhancing insulin action, glucose transport, and adi-
ponectin in adipocytes, skeletal muscle, and pancreatic 
beta cells.24,25
A meta-analysis of six studies assessing the efficacy 
of topiramate for weight loss over 24 weeks found that the 
percentage weight loss in topiramate-treated individuals was 
6.5% (CI: 4.8%–8.3%).17 A sensitivity analysis assuming no 
weight loss among individuals lost to follow-up demonstrated 
a 3.6% mean weight loss with topiramate (CI: 2.6–4.8%).17 
The degree of topiramate-associated weight loss appears to 
correspond to baseline body weight (ie, obese individuals lost 
a higher percentage of body weight compared to normal or 
overweight individuals).26
Despite topiramate’s proven efficacy, its high incidence 
of adverse effects has prevented its use as an obesity 
 monotherapy. Dose-dependent neuropsychiatric and cogni-
tive adverse effects have been reported,27,28 while its effects 
on carbonic anhydrase inhibition can lead to paresthesia and 
other complications associated with metabolic acidosis.46,47 
Rarely, topiramate is associated with vision disturbances, the 
most serious of which are severe acute myopia and secondary 
angle-closure glaucoma.
Orlistat
Orlistat is a pancreatic lipase inhibitor that reduces the 
metabolism and thus the absorption of some dietary fats by 
binding to lipase in the gut lumen, inhibiting ∼30% of fat 
absorption. It is the only obesity therapy currently approved 
in both Europe and the US for the long-term treatment of 
obesity, and it remains the only obesity therapy with long-
term safety and efficacy data.
Orlistat appears to be modestly effective in promoting 
weight loss, and thus although it is indicated for the long-
term treatment of obesity, weight loss maintenance remains 
 difficult. Accordingly, attrition rates average 33% in  studies.29 
A Cochrane meta-analysis of randomized controlled trials 
showed an average greater weight reduction of 2.9% in 
patients who received orlistat as an adjunct to lifestyle modifi-
cation (CI: 2.5%–3.4%) compared to placebo, with equivalent 
weight regain in both groups over time.30 A meta-analysis of 
22 studies of orlistat over 12 months demonstrated a 2.89 kg 
(CI: 2.27–3.51 kg) associated weight loss compared to pla-
cebo, with total weight loss in the orlistat-treated patients 
of 8.13 kg.17
Orlistat also appears to have beneficial effects on meta-
bolic parameters. A 4-year Swedish randomized controlled 
trial of 3,305 nondiabetic obese patients showed that orlistat 
therapy resulted in modest weight loss compared to placebo 
(5.8 kg versus 3.0 kg), and it reduced the risk of new onset 
diabetes mellitus by 37.3%.31 Orlistat has also been associ-
ated with improved lipid, independent of weight loss, and 
blood pressure parameters.31,32 The clinical utility of orlistat 
is limited predominantly by its gastrointestinal side effects; 
however, these are generally mild and mitigated on a low-
fat diet.30
Lorcaserin
Lorcaserin is a selective serotonin 2C receptor agonist that 
acts within the hypothalamus to decrease food intake by 
promoting increased satiety. This is mediated via release of 
melanotropin-α, which stimulates melanocortin receptor-4, 
resulting in appetite satiety.33 Three 1-year randomized, 
placebo-controlled Phase III trials have demonstrated that 
lorcaserin is associated with moderate weight loss in con-
junction with lifestyle interventions.34–36
The 2-year Behavioral Modification and Lorcaserin for 
Obesity and Overweight Management in Diabetes  Mellitus34 
(BLOOM) trial evaluated 3,182 overweight or obese individ-
uals (with $1 comorbidity, excluding diabetes), and demon-
strated significant weight loss in the lorcaserin versus placebo 
group after 1 year (mean weight loss: -5.8 kg and -2.2 kg, 
respectively). Overall, lorcaserin was associated with a 3.6% 
placebo-subtracted weight reduction after 1 year (5.8% 
weight loss with lorcaserin versus 2.2% for placebo). After 
1 year, 47.5% of individuals receiving  lorcaserin achieved 
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$5% weight loss and 22.6% achieved $10% weight loss 
compared to 20.3% and 7.7%, respectively, of those receiv-
ing placebo. After 2 years, although weight increased among 
individuals on lorcaserin therapy, long-term therapy was 
associated with lower mean body weight than either placebo 
or those receiving lorcaserin in year 1 followed by placebo.34 
The Behavioral Modification and Lorcaserin Second Study 
for Obesity Management35 (BLOSSOM) trial evaluated 
the efficacy of lorcaserin in 4,008 obese and overweight 
patients with obesity-related complications. It was found that 
lorcaserin was associated with a significantly greater mean 
percent weight loss compared with placebo (-2.8%, -4.7%, 
and -5.8% for placebo, lorcaserin 10 mg daily, and lorcaserin 
10 mg twice daily, respectively).
The effects of lorcaserin in 604 obese individuals 
with diabetes on therapy with variable glycemic control 
(hemoglobin A
1c
 [HbA
1c
] 7.0%–10.0%) were specifically 
evaluated in the Behavioral Modification and Lorcaserin for 
Obesity and Overweight Management in Diabetes Mellitus 
(BLOOM-DM) study.36 Almost 50% of individuals treated 
with lorcaserin achieved an HbA
1c
 ,7.0%, which correlated 
with the degree of weight loss achieved. However, these 
improvements in cardiometabolic risk were not durable. 
Although glycemic and lipid parameters appeared to be 
more favorable when compared with placebo in the first year 
of study, they were no longer significant by the end of the 
2 years, reflecting the effects of weight regain.36
Lorcaserin is generally well tolerated, with the most com-
mon adverse effects associated with its use including headache, 
dizziness, fatigue, and nausea. Although lorcaserin has a simi-
lar mechanism of action to fenfluramine and dexfenfluramine, 
its receptor specificity may attenuate the risk of valvulopathy 
or cardiovascular sequelae, as echocardiogram studies in the 
major clinical trials of lorcaserin were within normal range.34,35 
However, there is concern that the studies were not adequately 
powered to detect possible cardiovascular adverse effects, 
owing to the lower than expected event rate.37
Role of combination phentermine/
topiramate ER and comparative 
efficacy for obesity
Combination phentermine/topiramate ER was approved by 
the FDA in July 2012 for the long-term treatment of obe-
sity in obese or overweight individuals with obesity related 
co-morbidities at a recommended dose of 7.5/46 mg daily, 
in conjunction with lifestyle intervention. It has not been 
approved in Europe primarily due to the lack of long-term 
data on cardiovascular safety outcomes.
Efficacy
Combination pharmacotherapy for obesity aims to achieve 
greater overall weight loss by targeting multiple complemen-
tary pathways that regulate energy homeostasis, to overcome 
physiological counter-regulatory mechanisms that frequently 
lead to weight regain. It also allows lower and therefore bet-
ter tolerated doses of the therapy’s components to be used. 
Although there are no head-to-head studies, phentermine/
topiramate ER currently appears to be the most effective 
available obesity pharmacotherapy, although longer-term 
data are required.
Five recent key clinical trials have evaluated the efficacy, 
safety, and cardiometabolic effects of phentermine/ topiramate 
ER in conjunction with lifestyle modifications. The superior-
ity of combination pharmacotherapy was established in the 
28-week randomized controlled Phase III EQUATE study.38,39 
Obese patients (n=756) (BMI: 30–45 kg/m2) were randomized 
to one of seven treatment arms  (phentermine/topiramate ER 
mid-dose [7.5/46 mg] or full-dose [15/92 mg], phentermine 
7.5 mg or 15 mg, topiramate 46 mg or 92 mg, and a placebo 
arm). Both doses of phentermine/topiramate ER significantly 
reduced mean body weight compared to an equivalent mono-
therapy or placebo. Mid- and full-dose phentermine/topiramate 
ER was associated with mean reductions in weight of 8.5% and 
9.2%, respectively, compared to 1.7% for placebo, 6.1% for 
full-dose phentermine, and 6.4% for full-dose topiramate.38
The 1-year EQUIP study randomized 1,287 participants 
with a BMI $35 kg/m2 without significant comorbidities to 
either placebo, low-dose (3.75/23 mg), or high-dose (15/92 mg) 
phentermine/topiramate ER in conjunction with a lifestyle 
intervention.41 Phentermine/topiramate ER was associated 
with significantly greater weight reductions from baseline, 
with a mean body weight decrease of 10.9% with full-dose 
phentermine/topiramate ER, 5.1% with low-dose phenter-
mine/topiramate ER, versus 1.6% with placebo.  Overall, phen-
termine/topiramate ER produced a 9.4% placebo-subtracted 
weight reduction after 1 year. Significantly more participants 
on phentermine/topiramate ER achieved $5% and $10% 
weight loss compared to placebo: 66.7% and 47.2% on the 
full dose, 44.9% and 18.8% on the low dose, versus 17.3% 
and 7.4% for placebo, respectively.41
The largest of these trials, CONQUER, assessed the 
safety, efficacy and impact on the cardiometabolic seque-
lae of obesity of phentermine/topiramate ER in 2,487 
 overweight and obese participants (BMI: 27–45 kg/m2) with 
two or more obesity-related comorbidities. Participants were 
randomized to placebo, mid-dose (7.5/46 mg), or high-dose 
(15/92 mg) phentermine/topiramate ER over the course of 
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56 weeks.27 Phentermine/topiramate ER was associated with 
significantly greater weight loss (-1.4 kg for placebo, -8.1 
kg for mid-dose, and -10.2 kg for high-dose therapy), as 
well as greater maintenance of weight loss. Mean weight loss 
from baseline in the placebo, mid-, and full-dose groups was 
1.2%, 7.8%, and 9.8%, respectively. Weight loss of $5% and 
$10%, respectively, occurred in 21% and 7% of individuals 
in the placebo arm, 62% and 37% in the mid-dose arm, and 
70% and 48% in the high-dose arm.27
The SEQUEL study demonstrated the durability of weight 
loss maintenance with phentermine/topiramate ER in obese 
individuals with comorbidities. SEQUEL was a 2-year exten-
sion study, enrolling 676 subjects who had participated in the 
CONQUER trial for an additional 52 weeks, maintaining their 
original randomized treatment assignment.42 Six hundred and 
seventy-six of a total 866 eligible participants continued in 
the extension study, with 84% completing the study overall. 
Weight gain occurred in all groups; however, the mean 
weight loss at the end of 2 years was greater with both mid- 
(–9.3%) and high-dose (–10.5%) phentermine/topiramate 
ER versus -1.8% for the placebo group. In addition, 79.3% 
of participants in the high-dose and 75.2% in the mid-dose 
phentermine/topiramate ER groups achieved a $5% reduc-
tion in mean body weight from baseline, compared to 30% 
in the placebo group, while 53.9% of participants in the mid-
dose and 50.3% in the high-dose phentermine/topiramate ER 
groups achieved $10% weight loss.42 The impact of selection 
bias must be taken into account in interpreting these results, 
as the study cohort in the SEQUEL trial consisted only of 
patients who completed the CONQUER study, and these 
patients were presumably responders and well motivated.
Cardiometabolic parameters
The majority of morbidity and mortality outcomes in obesity 
relate to complications from cardiometabolic disease, and 
even modest weight reductions and decreased waist circumfer-
ence are associated with improvements in several cardiometa-
bolic parameters, including systemic arterial pressure, lipid 
profile and blood glucose levels.8 As phentermine/ topiramate 
ER appears to be a potent obesity pharmacotherapy, any 
subsequently achieved weight loss would be expected to 
have a favorable impact on cardiometabolic risk factors, with 
the caveat of the known adverse cardiovascular risk profile 
associated with its constituent monotherapies.
Treatment with phentermine/topiramate ER is associated 
with favorable blood pressure and lipid profiles, as summa-
rized in Table 1. The EQUIP study demonstrated significant 
reductions in both systolic and diastolic blood pressure, 
and an improved lipid profile among those individuals on 
high-dose phentermine/topiramate ER, although this study 
group was characterized by a relative lack of obesity-related 
comorbidities.41 The CONQUER trial also confirmed signifi-
cant improvements in systolic blood pressure, triglycerides, 
and high-density lipoprotein cholesterol with both doses of 
phentermine/topiramate ER, in addition to small, but statisti-
cally significant, reductions in diastolic blood pressure and 
low-density lipoprotein cholesterol with full-dose phenter-
mine/topiramate ER.27 The SEQUEL trial demonstrated the 
durability of improvements in cardiometabolic disease with 
ongoing reductions in systolic and diastolic blood pressure, 
necessitating a decrease in antihypertensive therapies, as 
well as sustained improvements in glycemic control and 
lipid profiles.42
The CONQUER trial demonstrated significant improve-
ments in relation to glycemic profiles.27 Participants with 
diabetes mellitus treated with phentermine/topiramate ER 
had greater improvements in glycemic parameters compared 
to placebo after 1 year, with significant reductions in HbA
1c
, 
fasting blood glucose, and insulin levels following an oral 
glucose tolerance test. Only 1.5% and 0.6% of participants 
with diabetes mellitus in the mid- and high-dose phentermine/
topiramate ER groups, respectively, required an escalation 
in oral hypoglycemic medication compared to 12% in the 
placebo group. There was also less progression to diabetes 
mellitus in the phentermine/topiramate ER group, with the 
annualized incidence rate for the development of diabetes 
at 9.0% for placebo, 6.7% for mid-dose, and 4.4% for high-
dose phentermine/topiramate ER.27 A 1-year randomized 
controlled trial of full-dose phentermine/topiramate ER in 
130 obese subjects with diabetes mellitus on either diet-
control or oral hypoglycemic agents demonstrated an HbA
1c
 
reduction of 1.6% (versus 1.1% in the placebo group), cor-
relating with increased use of oral hypoglycemic agents in the 
 placebo group versus an overall decrease in the phentermine/
topiramate ER group.42
The effect of phentermine/topiramate ER on obstructive 
sleep apnea has also been assessed in a small single-center 
trial over 28 weeks, demonstrating an improved apnea–
hypopnea index in the treatment arm compared to placebo. 
The reduction in body weight correlated positively with 
improvements in the apnea–hypopnea index score.43
Safety and tolerability
Combination pharmacotherapy is theoretically associated 
with improved tolerability through lower doses of constituent 
monotherapy which, in turn, enables sustained weight loss 
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Table 1 Comparison of efficacy and safety of orlistat, lorcaserin, and phentermine/topiramate ER for weight loss and cardiometabolic 
parameters
Parameter Orlistat17 Lorcaserin Phentermine/topiramate ER
Phase III clinical trials BLOSSOM35 BLOOM34 BLOOM (extension)36 EQUATE38,39 EQUIP41 CONQUER27
Study arm (placebo,  
dose [mg])
Placebo 10 mg 20 mg Placebo 20 mg Placebo 20 mg/ 
placebo
20 mg Placebo 7.5/46 mg 15/92 mg Placebo 3.75/23 mg 15/92 mg Placebo 7.5/46 mg 15/92 mg
enrolled (n) 13,759* 1,601 801 1,602 1,499 1,538 697 283 573 103 103 103 514 241 512 994 498 995
Completed study, n (%) 834 (52) 473 (59) 917 (57) 716 (45) 883 (55) 550 (79) 195 (69) 383 (67) 69 (63) 73 (69) 68 (63) 241 (47) 138 (57) 301 (59) 616 (62) 374 (75) 733 (74)
Efficacy
1. weight loss
Kg (%) -2.39 -2.8 
(-2.9)
-4.7 
(-4.7)
-5.8 
(-5.8)
-2.2 
(-2.2)
-5.8 
(-5.8)
-2.4 
(-2.4)
-3.3 
(-3.3)
-5.6 
(-5.6)
-1.5 
(-1.5)
-8.4 
(-8.2)
-8.9 
(-9.0)
-1.8 
(-1.6)
-6.0 
(-5.1)
-12.6 
(-10.9)
-1.4 
(-1.2)
-8.1 
(-7.8)
-10.2 
(-9.8)
 Placebo corrected (%)/ 
weighted mean difference**
-2.9** -1.8 -2.9 -3.6 -0.9 -3.2 -6.8 -7.5 -3.5 -9.3 -6.6 -8.6
2. Cardiometabolic effects
waist circumference (cm) – -1.7 -2.2 -2.9 -0.76 -2.43 -5.5 -5.4 -2.5 -7.8 -5.2 -6.8
Systolic BP (mmHg) -1.85 -0.1 -0.7 -0.6 1.4 -1.0 -5.2 -3.4 -2.7 -3.8 -2.3 -3.2
 Fasting blood glucose  
level (mmol/L)
-0.12# -0.11 -0.01 -0.09 0.01 -0.02 -0.06 -0.14 -0.12 -0.20
Change in heart rate (bpm) -0.2 -0.3 1.2 -0.1 0.1 1.7
  Total cholesterol (%LS)† -0.27# -1.3 -0.7 -1.47 0.16 -1.17 -2.6 -1.4 -1.9 -2.5 -1.6 -3
  HDL (%LS)† -0.02# 2.2 2.4 0.26 3.12 1.69 1.8 2.1 0.5 3.5 4 5.6
  LDL -0.21#
  Triglycerides (%LS)† -0.00# -4.6 -3.4 -6.0 -1.44 9.12 -1.6 -12.6 -3.9 -14.3 -13.3 -15.3
Safety
Serious adverse events (%) 2.2 3.4 3.1 2.5 2.7 3.6 2.8 3.0 3.5 3.0 4.0 2.5 2.5 2.5 4.0 3.0 5.0
Most common adverse events 
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Dizziness 
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Key FDA safety concerns Carcinogenicity 
valvulopathy 
Cardiovascular risk
Depression 
Neurocognitive sequelae 
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Birth defects
Notes: *Data from Zhou et al.48 effect of anti-obesity drug on cardiovascular risk factors: A systematic review and meta-analysis of randomised controlled trials. PLoS One. 
2012;7(6):e39062. Twenty-one RCTs met the inclusion criteria; **Data from Padwal et al.30 Long-term pharmacotherapy for obesity and overweight (Review). Cochrane 
Database of Systematic Reviews. 2003;CD004094; †%LS; #mmol/L; ##applicable to higher dose therapy only for phentermine/topiramate eR. Rate of headache: 6.4% in the 
BLOOM (extension) study.
Abbreviations: ER, extended release; BLOSSOM, Behavioral Modification and Lorcaserin Second Study for Obesity Management; BLOOM, Behavioral Modification and 
Lorcaserin for Obesity and Overweight Management; n, number; BP, blood pressure; %LS, percentage least squares; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; FDA, US Food and Drug Administration; RCT, randomized controlled trial.
maintenance. This rationale is evident with the use of ER 
topiramate in phentermine/topiramate ER, enabling a longer 
duration of action with daily dosing, and improving toler-
ability compared to the immediate-release formulation.
Key safety considerations for phentermine/topiramate ER 
arise from the known adverse effect profiles of the constituent 
drugs, specifically potential teratogenicity, cardiovascular and 
neurocognitive sequelae, and metabolic acidosis.20 Accord-
ingly, phentermine/topiramate ER is not recommended in 
individuals with recent/unstable vascular disease, signifi-
cant active depression or suicidal ideation/previous suicide 
attempts, and it is contraindicated in those with glaucoma 
and hyperthyroidism.39
Common adverse events
Phentermine/topiramate ER appears to be generally well tol-
erated, as adverse events are predominantly dose-related and 
alleviated over time; this is evident with the significantly lower 
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Table 1 Comparison of efficacy and safety of orlistat, lorcaserin, and phentermine/topiramate ER for weight loss and cardiometabolic 
parameters
Parameter Orlistat17 Lorcaserin Phentermine/topiramate ER
Phase III clinical trials BLOSSOM35 BLOOM34 BLOOM (extension)36 EQUATE38,39 EQUIP41 CONQUER27
Study arm (placebo,  
dose [mg])
Placebo 10 mg 20 mg Placebo 20 mg Placebo 20 mg/ 
placebo
20 mg Placebo 7.5/46 mg 15/92 mg Placebo 3.75/23 mg 15/92 mg Placebo 7.5/46 mg 15/92 mg
enrolled (n) 13,759* 1,601 801 1,602 1,499 1,538 697 283 573 103 103 103 514 241 512 994 498 995
Completed study, n (%) 834 (52) 473 (59) 917 (57) 716 (45) 883 (55) 550 (79) 195 (69) 383 (67) 69 (63) 73 (69) 68 (63) 241 (47) 138 (57) 301 (59) 616 (62) 374 (75) 733 (74)
Efficacy
1. weight loss
Kg (%) -2.39 -2.8 
(-2.9)
-4.7 
(-4.7)
-5.8 
(-5.8)
-2.2 
(-2.2)
-5.8 
(-5.8)
-2.4 
(-2.4)
-3.3 
(-3.3)
-5.6 
(-5.6)
-1.5 
(-1.5)
-8.4 
(-8.2)
-8.9 
(-9.0)
-1.8 
(-1.6)
-6.0 
(-5.1)
-12.6 
(-10.9)
-1.4 
(-1.2)
-8.1 
(-7.8)
-10.2 
(-9.8)
 Placebo corrected (%)/ 
weighted mean difference**
-2.9** -1.8 -2.9 -3.6 -0.9 -3.2 -6.8 -7.5 -3.5 -9.3 -6.6 -8.6
2. Cardiometabolic effects
waist circumference (cm) – -1.7 -2.2 -2.9 -0.76 -2.43 -5.5 -5.4 -2.5 -7.8 -5.2 -6.8
Systolic BP (mmHg) -1.85 -0.1 -0.7 -0.6 1.4 -1.0 -5.2 -3.4 -2.7 -3.8 -2.3 -3.2
 Fasting blood glucose  
level (mmol/L)
-0.12# -0.11 -0.01 -0.09 0.01 -0.02 -0.06 -0.14 -0.12 -0.20
Change in heart rate (bpm) -0.2 -0.3 1.2 -0.1 0.1 1.7
  Total cholesterol (%LS)† -0.27# -1.3 -0.7 -1.47 0.16 -1.17 -2.6 -1.4 -1.9 -2.5 -1.6 -3
  HDL (%LS)† -0.02# 2.2 2.4 0.26 3.12 1.69 1.8 2.1 0.5 3.5 4 5.6
  LDL -0.21#
  Triglycerides (%LS)† -0.00# -4.6 -3.4 -6.0 -1.44 9.12 -1.6 -12.6 -3.9 -14.3 -13.3 -15.3
Safety
Serious adverse events (%) 2.2 3.4 3.1 2.5 2.7 3.6 2.8 3.0 3.5 3.0 4.0 2.5 2.5 2.5 4.0 3.0 5.0
Most common adverse events 
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valvulopathy 
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Tachycardia 
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Notes: *Data from Zhou et al.48 effect of anti-obesity drug on cardiovascular risk factors: A systematic review and meta-analysis of randomised controlled trials. PLoS One. 
2012;7(6):e39062. Twenty-one RCTs met the inclusion criteria; **Data from Padwal et al.30 Long-term pharmacotherapy for obesity and overweight (Review). Cochrane 
Database of Systematic Reviews. 2003;CD004094; †%LS; #mmol/L; ##applicable to higher dose therapy only for phentermine/topiramate eR. Rate of headache: 6.4% in the 
BLOOM (extension) study.
Abbreviations: ER, extended release; BLOSSOM, Behavioral Modification and Lorcaserin Second Study for Obesity Management; BLOOM, Behavioral Modification and 
Lorcaserin for Obesity and Overweight Management; n, number; BP, blood pressure; %LS, percentage least squares; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; FDA, US Food and Drug Administration; RCT, randomized controlled trial.
incidence of adverse effects in the SEQUEL versus CONQUER 
studies.27,42 Common adverse events include  paresthesia, 
dry mouth, dizziness, dysgeusia, headache, insomnia, and 
 constipation. Discontinuation rates due to adverse events were 
9%, 12%, and 18% for placebo, low- and mid-dose, and high-
dose phentermine/topiramate ER, respectively.27,40,42 Overall, 
there was a higher study completion rate in those taking phen-
termine/topiramate ER compared with placebo, likely because 
of the greater weight loss efficacy of the intervention over 
placebo, and/or the effect of topiramate-mediated amelioration 
in food-addictive behavior.40
Cardiovascular concerns
The major concern regarding phentermine/topiramate ER 
relates to its possible deleterious effects on cardiovascular 
endpoints, as phentermine has been associated with an 
increase in heart rate.27,41 Evidence thus far indicates that 
this therapy is associated with only small increases in mean 
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heart rate, with mid- and full-dose phentermine/ topiramate 
ER associated with a mean increase in heart rate of 0.6 bpm 
and 1.6 bpm, respectively, as compared with no change in the 
placebo-treated group.27,41 A greater proportion of individuals 
had a documented increase in heart rate when compared to 
placebo-treated patients, with 13.5% of individuals treated 
with the mid-dose, 19.6% with the full dose, and 11.9% on 
placebo reporting an increase in heart rate from baseline of 
.20 bpm.27,41 The clinical significance of this is unclear; 
however, at this stage, this finding does not appear to be 
associated with any compromise in cardiac function and the 
changes in heart rate correlate with improvements in blood 
pressure parameters.27,41 Nevertheless, long-term cardio-
vascular safety data are required, particularly in individuals 
with more unstable cardiovascular disease, in view of the 
poor history of obesity pharmacotherapy characterized by 
significant adverse cardiovascular signals identified during 
post-marketing surveillance. Based on the interpretation of 
data in the SCOUT study,9 adverse cardiovascular events 
should be attenuated by appropriate patient selection for 
pharmacotherapy and continued pharmaco-vigilance, such 
that if a patient does not lose weight on a particular therapy, 
then that therapy should be discontinued.
Neurocognitive sequelae
Both phentermine and topiramate are associated with worsen-
ing mood disorders and suicidal ideation via central nervous 
system effects.27,28 To date, there is no evidence that combina-
tion pharmacotherapy significantly increases  moderate/severe 
depression or suicidality in individuals with mild depression 
on stable doses of antidepressants. However, the clinical 
trials demonstrate that individuals receiving higher dose 
phentermine/topiramate ER compared to placebo were up 
to sevenfold more likely to cease therapy because of mental 
health-related effects.27,28
Topiramate is also associated with cognitive dysfunc-
tion, including language difficulties, attention and memory 
impairment, and confusion.22,27,28 These effects were seen in 
individuals on phentermine/topiramate ER, with disturbances 
in attention occurring most often. The incidence of neu-
rocognitive adverse effects was 2.0% for low-dose, 5.6% for 
mid-dose, and 7.8% for full-dose phentermine/topiramate ER 
compared to 1.7% for placebo.20
Teratogenicity and contraception 
considerations
The teratogenic potential of obesity pharmacotherapy is 
a major concern, as these agents are frequently used in 
women of childbearing potential. Moreover, topiramate 
may alter the pharmacokinetics of the oral contraceptive 
pill, with evidence suggesting that ethinyl estradiol levels 
may be decreased by 16%, theoretically decreasing con-
traceptive  efficacy.20 Accordingly, the FDA has developed 
guidelines to ensure that women of childbearing potential 
are informed of the possible teratogenic risks of the treat-
ment, recommending that pregnancy testing be conducted 
prior to initiation of phentermine/topiramate ER, and 
suggesting that monthly pregnancy testing be performed 
thereafter.20 In addition, consistent use of effective contra-
ception is essential.
FDA approval for phentermine/topiramate ER was con-
tingent on an analysis of the potential risk of teratogenicity 
associated with its use, based on outcomes among infants 
born to mothers exposed to topiramate during pregnancy.44 
The prevalence of oral clefts (cleft lip with or without cleft 
palate) was twofold greater in pregnancies exposed to topira-
mate, with an estimated prevalence rate among those actively 
using topiramate of 0.29%, compared to 0.16% in previously 
exposed women.45,46
Other adverse events
Topiramate is associated with metabolic acidosis via carbonic 
anhydrase inhibition.46,47 Accordingly, a small decrease in 
serum bicarbonate concentration has been observed in all 
 phentermine/topiramate ER studies without clinically signifi-
cant metabolic acidosis, and serum bicarbonate levels tended 
to return to baseline over time.27,41,42 However, the paresthesia 
commonly seen with therapy is most likely associated with 
serum bicarbonate alterations. Chronic severe metabolic 
acidosis may lead to osteomalacia, osteoporosis, and renal 
calculi;47 however, these outcomes have not been seen in the 
trials to date.
Conclusion
Lifestyle interventions with adjunctive pharmacotherapy 
and bariatric surgery are the established approaches used 
to manage obesity and its cardiometabolic sequelae. 
Although lifestyle modification remains the cornerstone 
of obesity interventions, its effectiveness is frequently 
limited by significant weight regain in the long-term. 
Accordingly, successful obesity management requires 
escalation of intervention in many individuals, and adjunc-
tive pharmacotherapy appears to be increasingly effective 
in this regard. It seems reasonable that pharmacotherapy 
be offered as an alternative intermediate option to lifestyle 
or bariatric surgery, expanding the current armamentarium 
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of obesity management. The weight loss achieved by 
pharmacotherapy is in between that commonly achieved 
by lifestyle intervention and bariatric surgery. However, 
pharmacotherapy would ideally obviate the need for 
surgery in some individuals, providing it demonstrates a 
favorable cardiometabolic profile.
The burgeoning obesity epidemic arguably necessitates 
a paradigm shift in the current approach to obesity manage-
ment, with greater consideration for the role of long-term 
pharmacotherapy to assist and maintain weight loss.  Obesity 
must be conceptualized as a chronic disease associated 
with multiple comorbidities and, thus, any treatment approach 
must also be multifaceted and reflect the complex etiology 
of obesity.
Combination pharmacotherapy has theoretical appeal, 
as it better reflects the multiple pathophysiological mecha-
nisms of obesity. Phentermine/topiramate ER thus currently 
demonstrates greater efficacy than monotherapy through its 
synergistic potential and multiple mechanisms of action, while 
its improved tolerability reinforces the role of combination 
pharmacotherapy in long-term weight loss maintenance. 
Current evidence suggests a positive, durable effect of phen-
termine/topiramate ER on the cardiometabolic sequelae of 
obesity, including improving  glycemia and blood pressure, and 
ameliorating obstructive sleep apnea. More long-term efficacy 
and safety data are however required given the poor history of 
obesity pharmacotherapy.
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